logo

For the Inventor, By the Inventor

Bothell, WA, United States of America

Seagen Inc.


USPTO Granted Patents = 64



Trademarks = 27

Forward Citations = 48

Loading Chart...
Loading Chart...

97 inventors (with patents filed for the assignee):

goldMedal Lori Westendorf (9 out of 11 patents)

silverMedal Shyra Gardai (7 out of 8 patents)

bronzeMedal Django Sussman (7 out of 20 patents)

4.  Patrick J Burke (7 out of 26 patents)

5.  Dana Kennedy (6 out of 12 patents)

6.  Peter Senter (6 out of 47 patents)

7.  Eric Sievers (5 out of 16 patents)

8.  Robert Lyon (5 out of 8 patents)

9.  Scott Peterson (4 out of 6 patents)

10.  Che-Leung Law (4 out of 19 patents)

11.  Scott C Jeffrey (4 out of 30 patents)

12.  Karen Jane Meyrick Morrison (4 out of 66 patents)

13.  Vivian Trang (4 out of 4 patents)

14.  Matthew R Levengood (4 out of 4 patents)

15.  Travis Biechele (4 out of 4 patents)


Core Competencies:
Anti-PD-L1 Antibodies
Antibody-Drug Conjugates
Hydrophilic Conjugates
CD47 Antibodies
HER2 Positive Cancers
Glycan-Interacting Compounds
Non-Fucosylated Antibodies
Combination Therapy
Selective Drug Release
Cysteine Mutated Antibodies
Auristatin Compounds
BCMA Antibodies

64 patents:

1. 12421312 - Anti-PD-L1 antibodies and antibody-drug conjugates (2025-09-23),
2. 12268751 - Anti-αVβ6 antibodies and antibody-drug conjugates (2025-04-08),
3. 12257340 - Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof (2025-03-25),
4. 12257281 - Hydrophilic antibody-drug conjugates (2025-03-25),
5. 12194321 - Camptothecin conjugates (2025-01-14),
6. 12071480 - CD47 antibodies and uses thereof for treating cancer (2024-08-27),
7. 12048698 - Treatment of HER2 positive cancers (2024-07-30),
8. 12036286 - Selective drug release from internalized conjugates of biologically active compounds (2024-07-16),
9. 11944689 - Drug conjugates with self-stabilizing linkers having improved physiochemical properties (2024-04-02),
10. 11938194 - Cysteine mutated antibodies for conjugation (2024-03-26),
11. 11931414 - Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates (2024-03-19),
12. 11891644 - T cells with reduced surface fucosylation and methods of making and using the same (2024-02-06),
13. 11857565 - Hydrophobic Auristatin F compounds and conjugates thereof (2024-01-02),
14. 11844839 - Process for the preparation of pegylated drug-linkers and intermediates thereof (2023-12-19),
15. 11827709 - Anti-AVB6 antibodies and antibody-drug conjugates (2023-11-28),
Seagen Inc., formerly known as Seattle Genetics, is a biotechnology company that specializes in the development of targeted therapies for the treatment of cancer. The company uses its proprietary antibody-drug conjugate (ADC) technology to create innovative cancer treatments. Seagen focuses on advancing novel therapies that have the potential to improve patient outcomes and transform cancer treatment. With a commitment to scientific excellence and collaboration, Seagen is dedicated to making a meaningful impact in the lives of cancer patients.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

64 Patents

#8 in Bothell, WA

#101 in Washington

#5,446 in US

#11,029 in the World

...
Bothell, WA, United States of America

Seagen Inc.

Forward Citations = 48

97 inventors:

goldMedal Lori Westendorf (9 out of 11 patents)

silverMedal Shyra Gardai (7 out of 8 patents)

bronzeMedal Django Sussman (7 out of 20 patents)

4.  Patrick J Burke (7 out of 26 patents)

5.  Dana Kennedy (6 out of 12 patents)

Please report any incorrect information to support@idiyas.com
Loading…